LYCOS RETRIEVER 
Gene: Companies
built 292 days ago
Gene is a CPA and brings over 25 years of executive leadership in finance, operations, IT, sales and human resources. He has directed comprehensive change at several companies resulting in significant financial improvement, much higher customer retention, enhanced organizational performance, improved staff satisfaction and stronger business relationships.
Source:
Cell Genesys is pursuing gene therapies for hemophilia A and hemophilia B -- genetic deficiencies in factor VIII and factor IX clotting factor genes, respectively. Cell Genesys has four different gene delivery systems and is using this technology "toolbox" to capture multiple product opportunities. The company's proprietary vector technologies include AAV, lentiviral, adenoviral and retroviral vectors engineered to provide safe and efficient therapeutic gene expression. In Cell Genesys' preclinical program for hemophilia B, an AAV vector system is employed since the factor IX gene is small enough to fit in this vector. For hemophilia A, the company has the option of employing an AAV vector system if a truncated form of the factor VIII gene can be successfully applied or a lentiviral vector system if the full length gene is required for optimal production of the deficient clotting factor protein. Successful delivery of the clotting factor genes is expected to result in production of the clotting factor proteins, representing a potential new approach to the treatment for hemophilia patients.
Source:
LOS ANGELES, June 25 /PRNewswire/ -- Entravision Communications Corporation (NYSE: EVC) announced today that Eugenio (Gene) Bryan has been named Vice President of Sales for the company's radio division. Mr. Bryan will be responsible for overseeing and enhancing advertising sales for Entravision's radio group. He will report to Jeffery Liberman, President of Entravision's Radio Division and will be based at Entravision's offices in New York City.
Source:
FOSTER CITY, Calif., June 19 /PRNewswire/ -- Cell Genesys, today announced that in preclinical studies of hemophilia gene therapy, the delivery of the factor IX gene, a blood clotting gene, into the liver demonstrated clear treatment advantages compared to intramuscular injection. Animals that received the factor IX gene in the liver using an AAV (adeno-associated viral) gene delivery system exhibited stable production of the factor IX protein throughout the duration of the study whereas those that received intramuscular injections had no detectable levels of the protein primarily due to the formation of anti-factor IX antibodies. Based on these and other findings, the company has determined that it will not pursue intramuscular delivery in human hemophilia gene therapy studies. These data were published in a June issue of the journal, Blood, the official journal of the American Society of Hematology, by Dr. James G. McArthur and colleagues at Cell Genesys.
Source:
MORE ABOUT
Companies